IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Entry into a Material Definitive AgreementItem 1.01
Entry into a Material Definitive Agreement.
On October 10, 2018, Ionis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has entered into an exclusive, worldwide collaboration agreement with Roche for the development of IONIS-FB-LRx.
A copy of this press release is attached as Exhibit 99.1 to this Current Report and incorporated herein by reference.
On October 5, 2018, the Company and Akcea Therapeutics, Inc., an affiliate of the Company, announced that the U.S. Food and Drug Administration (FDA) has approved TEGSEDITM (inotersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. TEGSEDI is now approved in the U.S., the European Union and Canada.
A copy of the press release is attached as Exhibit 99.2 to this Current Report and incorporated herein by reference.
| Item 9.01. |
Financial Statements and Exhibits. |
(d) Exhibits
|
Press Release dated October 10, 2018. |
|
Press Release dated October 5, 2018. |
IONIS PHARMACEUTICALS INC ExhibitEX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Ionis Enters New Collaboration with Partner to Develop IONIS-FB-LRx for Complement-Mediated Diseases Transaction valued at up to $760 million,…To view the full exhibit click here
About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases.
